Press release
Hepatocellular Carcinoma Pipeline Outlook Report 2024 (Updated)
Hepatocellular Carcinoma Pipeline
Key Takeaways from the Hepatocellular Carcinoma Pipeline Report
• DelveInsight's Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.
• The leading companies working in the Hepatocellular Carcinoma Market include Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others.
• Promising Hepatocellular Carcinoma Pipeline Therapies in the various stages of development include lenvatinib, pembrolizumab (200 mg), Sorafenib, Enzalutamide, AZD9150, Nivolumab, and others.
• December 2023: AstraZeneca announced a study of Phase 1 & 2 clinical trials for AZD5851. A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
• December 2023: AbbVie announced a study of Phase 2 clinical trials for Budigalimab, Livmoniplimab, Lenvatinib and Sorafenib. A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC.
Request a sample and discover the recent advances in Hepatocellular Carcinoma Treatment Drugs @ Hepatocellular Carcinoma Pipeline Outlook Report- https://www.delveinsight.com/report-store/hepatocellular-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Hepatocellular Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatocellular Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Hepatocellular Carcinoma Overview
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. Cirrhosis is a significant step in viral carcinogenesis for hepatocellular carcinoma. Integration of the hepatitis B virus genome into the host genome is the primary pathogenesis for oncogenesis in HBV.
Find out more about Hepatocellular Carcinoma Treatment Landscape @ Drugs for Hepatocellular Carcinoma Treatment- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Hepatocellular Carcinoma Emerging Drugs Profile
• Namodenoson: Can-Fite BioPharma
• SRF388: Surface Oncology
• Porustobart: Harbour BioMed
• Fisogatinib: CStone Pharmaceuticals
• STP705: Sirnaomics
Hepatocellular Carcinoma Pipeline Therapeutics Assessment
There are approx. 90+ key companies which are developing the therapies for Hepatocellular Carcinoma. The Hepatocellular Carcinoma companies which have their Hepatocellular Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Can-Fite BioPharma.
DelveInsight's Hepatocellular Carcinoma Pipeline Report covers around 95+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Hepatocellular Carcinoma Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Learn more about the emerging Hepatocellular Carcinoma Pipeline Therapies @ Hepatocellular Carcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Hepatocellular Carcinoma Pipeline Report
• Coverage- Global
• Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Hepatocellular Carcinoma Companies- Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others.
• Hepatocellular Carcinoma Pipeline Therapies- lenvatinib, pembrolizumab (200 mg), Sorafenib, Enzalutamide, AZD9150, Nivolumab, and others.
Dive deep into rich insights for new drugs for Hepatocellular Carcinoma Treatment, Visit @ Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Hepatocellular Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hepatocellular Carcinoma- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Namodenoson: Can-Fite BioPharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SRF388: Surface Oncology
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. STP705: Sirnaomics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Hepatocellular Carcinoma Key Companies
21. Hepatocellular Carcinoma Key Products
22. Hepatocellular Carcinoma- Unmet Needs
23. Hepatocellular Carcinoma- Market Drivers and Barriers
24. Hepatocellular Carcinoma- Future Perspectives and Conclusion
25. Hepatocellular Carcinoma Analyst Views
26. Hepatocellular Carcinoma Key Companies
27. Appendix
For further information on the Hepatocellular Carcinoma Pipeline Therapeutics, reach out @ Hepatocellular Carcinoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://theventurecation.com/author/germanydennydones/
https://blogstudiio.com/fabry-disease-market-size/
https://meccapost.com/author/germanydennydones/
https://kitmaker.net/profile/yashveer-bhardwaj
http://www.costaricajobsearch.com/author/germanydennydones/
https://keralaclick.com/classified-advertising/user/profile/182882
https://aviator.forex.pm/?qa=user/germanydennydones
https://careers.coloradopublichealth.org/employers/2926283-delveinsight
https://www.heavyironjobs.com/profiles/4448319-denny-dones
https://jobs.blooloop.com/employers/2614577-delveinsight
https://www.animaljobsdirect.com/employers/2926436-delveinsight
https://jobs.windomnews.com/employers/2926467-delveinsight
https://jobs.fsoma.org/employers/2926471-delveinsight
https://jobs.thetab.com/employers/1458246-delveinsight
https://forum.squarespace.com/profile/421527-dennydonesgermany/?tab=field_core_pfield_1
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hepatocellular Carcinoma Pipeline Outlook Report 2024 (Updated) here
News-ID: 3443162 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Hepatocellular
Laboratory-Produced Molecule In The Hepatocellular Carcinoma Drugs Market Indust …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Hepatocellular Carcinoma Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for drugs used in hepatocellular carcinoma has seen significant expansion in the past few years. The market, which is predicted to rise from $1.16 billion in 2024 to $1.27 billion in…
Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular …
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Hepatocellular Carcinoma Drugs Market Size During the Forecast Period?
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025…
Hepatocellular Carcinoma Pipeline 2024
DelveInsight, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent…
Hepatocellular Carcinoma Market - Winning the Battle Against Hepatocellular: Bre …
Newark, New Castle, USA: The "Hepatocellular Carcinoma Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hepatocellular Carcinoma Market: https://www.growthplusreports.com/report/hepatocellular-carcinoma-market/8027
This latest report researches the industry structure, sales, revenue,…
Hepatocellular Carcinoma Market Insights, Forecast to 2030
The report extensively examines the global Hepatocellular Carcinoma market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Hepatocellular Carcinoma . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market…
Hepatocellular Carcinoma Drugs Market Opportunity Analysis, 2018-2026
Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes. The disease is found to occur mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy in addition to chemotherapy…
